Innovative Glycan-based analysis for Cancer diagnostics

Project description

A sensitive diagnostic for prostate cancer

The prostate-specific antigen (PSA) is currently used as a biomarker for prostate cancer. However, PSA tests lack diagnostic accuracy as they have a high false positive rate, leading to wrong treatments and unnecessary prostate biopsies. To address this problem, scientists of the EU-funded GlyCan project have developed an innovative diagnostic assay capable of detecting glycan changes on the PSA protein. The test has 86 % accuracy and can discriminate between the healthy and the abnormal form of the protein. The GlyCan approach offers a reliable method for analysing complex biomolecules, and its use can also extend to other diseases.

Fields of science

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• natural sciences › biological sciences › biochemistry › biomolecules › carbohydrates
• social sciences › economics and business › business and management › business model
• medical and health sciences › clinical medicine › cancer › prostate cancer
• engineering and technology › medical engineering › medical laboratory technology › diagnostic technologies
• social sciences › economics and business › business and management › commerce

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

GLYCANOSTICS SRO

Address

Dubravska Cesta 9
845 38 Bratislava
Slovakia

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 50 000